GeoVax Labs, Inc. (Nasdaq: GOVX) today highlighted the strategic implications of recent research supporting its Gedeptin platform's potential to enhance immune checkpoint inhibitor activity and address checkpoint-resistant tumors. The company's announcement follows a peer-reviewed publication in JCI Insight titled “Broadening Activity of Checkpoint Blockade Agents by Intratumoral Nucleoside Cleavage,” which reported findings that Gene-Directed Enzyme-Prodrug Therapy (GDEPT) could enhance checkpoint inhibitor responses and activate systemic anti-tumor immunity in preclinical models of triple-negative breast cancer.
The broader oncology industry is increasingly focused on immune-priming approaches to overcome resistance to checkpoint inhibitors, which are foundational therapies in modern oncology but often fail in tumors with limited immune-cell infiltration—so-called “cold” tumors. GeoVax recently explored this challenge in an Onco'Zine commentary by Chairman and CEO David Dodd, titled “The Cold Tumor Barrier: Why Promising Oncology Therapies Fail In Vivo – and What It Will Take to Overcome It.” The article underscored that future advances may depend on improving tumor responsiveness through immune activation and microenvironment modulation.
“One of the most significant challenges in oncology today is the cold tumor barrier,” said David Dodd. “Checkpoint inhibitors can be highly effective when sufficient immune activity already exists within a tumor. However, many tumors remain largely invisible to the immune system. The next major opportunity may lie in therapies capable of activating immune recognition and making these tumors more responsive to existing immunotherapies.”
GeoVax sees Gedeptin as a potential complement, not competitor, to checkpoint inhibitors. The platform combines localized tumor destruction with bystander killing, tumor microenvironment remodeling, and immune activation. “The medical proposition is to improve responses where checkpoint inhibitors alone have not achieved their full potential; also representing a significant commercial opportunity with multiple partnering avenues,” Dodd added.
The company's lead clinical focus is a planned neoadjuvant study in recurrent head and neck squamous cell carcinoma (HNSCC), evaluating intratumoral Gedeptin with PD-1-based immunotherapy and standard of care. Recurrent head and neck cancer is considered attractive due to accessible tumors, integrated checkpoint inhibitors in standard care, and high unmet need. The neoadjuvant setting is suited for immune-priming approaches, as the intact tumor can stimulate broader anti-tumor immune responses before surgery.
“As checkpoint inhibitors continue moving earlier in the treatment paradigm, opportunities are emerging for therapies designed to improve immune responsiveness before surgery and potentially improve long-term outcomes,” said Dodd. Gedeptin's biologic profile aligns with this strategy, and the company sees applicability across multiple solid tumors where response rates remain suboptimal.
GeoVax is a clinical-stage biotechnology company developing immunotherapies and vaccines for solid tumors and infectious diseases. Its priority program is GEO-MVA, an MVA-based vaccine for mpox and smallpox, advancing toward a Phase 3 trial in 2026. In oncology, Gedeptin uses a non-replicating adenoviral vector encoding purine nucleoside phosphorylase, which converts the prodrug fludarabine into a localized cytotoxic compound. The company plans continued evaluation of Gedeptin in combination with checkpoint inhibitors, including pembrolizumab-based regimens.
